Voyager Therapeutics to Participate in Upcoming Investor Conferences
Voyager Therapeutics, a biotechnology firm focused on gene therapy and neurology, announced its participation in several upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Voyager Therapeutics, a biotechnology firm focused on gene therapy and neurology, announced its participation in several upcoming investor conferences. Key events include:
- SVB Securities Global Biopharma Conference (Virtual) – February 16, 2023, at 1:40 p.m. ET
- Cowen 43rd Annual Health Care Conference, Boston, MA – March 6, 2023, at 10:30 a.m. ET
- Oppenheimer 33rd Annual Healthcare Conference (Virtual) – March 13, 2023, at 8:40 a.m. ET
Webcasts of these sessions will be available on Voyager's website for 30 days post-event. The company utilizes its TRACER™ AAV capsid discovery platform to enhance gene therapy delivery and addresses neurological disorders.
Details
News Market Reaction – VYGR
The recorded move for VYGR in the trading session of this news was -0.12%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that management will participate in the following investor conferences:
- SVB Securities Global Biopharma Conference (Virtual) – Company presentation, February 16, 2023, 1:40 p.m. ET
- Cowen 43rd Annual Health Care Conference, Boston, MA – Panel discussion, March 6, 2023, 10:30 a.m. ET
- Oppenheimer 33rd Annual Healthcare Conference (Virtual) – Company presentation, March 13, 2023, 8:40 a.m. ET
The sessions may be accessed from the Investors section of Voyager’s website at www.voyagertherapeutics.com. Replays of the webcasts will be archived on Voyager’s website for at least 30 days.
About Voyager Therapeutics
Voyager Therapeutics (Nasdaq: VYGR) is a biotechnology company dedicated to breaking through barriers in gene therapy and neurology. The potential of both disciplines has been constrained by delivery challenges; Voyager is leveraging cutting-edge expertise in capsid discovery and deep neuropharmacology capabilities to address these constraints. Voyager’s TRACERTM AAV capsid discovery platform has generated novel capsids with high target delivery and blood-brain barrier penetration at low doses, potentially addressing the narrow therapeutic window associated with conventional gene therapy delivery vectors. This platform is fueling alliances with Pfizer Inc., Novartis and Neurocrine Biosciences as well as multiple programs in Voyager’s own pipeline. Voyager’s pipeline includes wholly-owned and collaborative preclinical programs in Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and Friedreich’s Ataxia, each with validated targets and biomarkers to enable a path to rapid potential proof-of-biology. For more information, visit www.voyagertherapeutics.com.
Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.
Contacts
Investors
Andrew Funderburk
afunderburk@kendallir.com
Media
Peg Rusconi
prusconi@vergescientific.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.